Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test

Rodríguez-Trabado, A.; Pereira, Luis Miguel Fernández; Romero-Chala, Silvia; García-Trujillo, José Antonio; Hijón, Carmen Cámara

doi:10.1016/j.aller.2011.09.009

Cited by 9 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, several studies have found a very high correlation (up to 95.5%) between the CD63 expression on basophils and the ASST in the diagnostic workup of autoimmune CSU [28,29]. Furthermore, CD63 expression has been suggested to be suitable for monitoring disease activity and the response to therapy in patients with urticaria and in patients with atopic disease [18,28,30,31]. Hence, the BAT using CD63 as the activation marker is a valuable tool in the diagnostic workup of CSU patients.…”

Section: Discussionmentioning

confidence: 99%

Positive CD63 Basophil Activation Tests Are Common in Children with Chronic Spontaneous Urticaria and Linked to High Disease Activity

Netchiporouk¹,

Moreau²,

Rahme³

et al. 2016

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: The basophil activation test (BAT) using CD63 expression is a sensitive and specific tool for the diagnostic workup of autoimmune chronic spontaneous urticaria (CSU). The definition of a positive BAT is directly dependent on the reference range and the cutoff values established in control populations. As of now, the pediatric reference range and cutoff values of the CD63 BAT remain to be established. Methods: In this study, we analyzed CD63 expression in 80 children (1-17 years old) without chronic urticaria (i.e., controls) and compared the values to those of a pediatric cohort of 105 CSU patients and 23 physical urticaria (PU) patients. Results: Based on the log-normal distribution of CD63 values in control subjects, the reference range and the cutoff for positive CD63 BAT values was established to be 1.2-1.8% (95% CI) and 1.8%, respectively. Children with CSU showed significantly elevated and significantly increased BAT values compared to healthy controls (Wilcoxon rank test p value <0.001). In contrast, no difference was found between BAT results in controls and PU patients. In pediatric CSU patients, a higher disease activity was associated with higher BAT values. Conclusions: Our study provides, for the first time, reference and cutoff values for the CD63 BAT in children. Our findings show that positive CD63 BAT are common in children with CSU and linked to a high disease activity.

show abstract

Section: Discussionmentioning

confidence: 99%

Positive CD63 Basophil Activation Tests Are Common in Children with Chronic Spontaneous Urticaria and Linked to High Disease Activity

Netchiporouk¹,

Moreau²,

Rahme³

et al. 2016

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…In recent years, several studies have indicated a role for the basophil activation tests in the diagnosis and follow‐up of food allergies, drug allergies, as well as for monitoring anti‐IgE treatments [B]. Lymphocyte activation tests might also be used in selected cases of food or drug‐related reactions [B and C].…”

Section: How – Practical Allergy Testingmentioning

confidence: 99%

Testing children for allergies: why, how, who and when

Eigenmann

Atanasković-Marković

Hourihane

et al. 2013

Pediatric Allergy Immunology

101

View full text Add to dashboard Cite

Allergic diseases are common in childhood and can cause a significant morbidity and impaired quality-of-life of the children and their families. Adequate allergy testing is the prerequisite for optimal care, including allergen avoidance, pharmacotherapy and immunotherapy. Children with persisting or recurrent or severe symptoms suggestive for allergy should undergo an appropriate diagnostic work-up, irrespective of their age. Adequate allergy testing may also allow defining allergic trigger in common symptoms. We provide here evidence-based guidance on when and how to test for allergy in children based on common presenting symptoms suggestive of allergic diseases.

show abstract

“…The basophil activation test and the autologous serum skin test (ASST) are in vitro and in vivo methods, respectively, that can identify the presence of autoantibodies in CU patients. 34 35 Basophil activation testing has been recently reviewed in detail 36 and is not well supported by evidence-based literature in the evaluation and management of CU. 1 2 In addition, skin testing for autoantibodies to the high-affinity IgE receptor or to IgE is not recommended.…”

Section: Introductionmentioning

confidence: 99%

Guideline of Chronic Urticaria Beyond

Fine

Bernstein

2016

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

Urticaria is a relatively common condition that if chronic can persist for weeks, months or years and affect quality of life significantly. The etiology is often difficult to determine, especially as it becomes chronic. Many cases of chronic urticaria are thought to be autoimmune, although there is no consensus that testing for autoimmunity alters the diagnostic or management strategies or outcomes. Many times, urticaria is easily managed with antihistamines and/or short courses of oral corticosteroids, but too often control is insufficient and additional therapies must be added. For years, immune modulating medications, such as cyclosporine and Mycophenolate Mofetil, have been used in cases refractory to antihistamines and oral corticosteroids, although the evidence supporting their efficacy and safety has been limited. Omalizumab was recently approved for the treatment of chronic urticaria unresponsive to H1-antagonists. This IgG anti-IgE monoclonal antibody has been well demonstrated to safely and effectively control chronic urticaria at least partially in approximately 2/3 of cases. However, the mechanism of action and duration of treatment for omalizumab is still unclear. It is hoped that as the pathobiology of chronic urticaria becomes better defined, future therapies that target specific mechanistic pathways will be developed that continue to improve the management of these often challenging patients.

show abstract

Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test

Cited by 9 publications

References 8 publications

Positive CD63 Basophil Activation Tests Are Common in Children with Chronic Spontaneous Urticaria and Linked to High Disease Activity

Positive CD63 Basophil Activation Tests Are Common in Children with Chronic Spontaneous Urticaria and Linked to High Disease Activity

Testing children for allergies: why, how, who and when

Guideline of Chronic Urticaria Beyond

Contact Info

Product

Resources

About